摘要
Abstract
Objective To investigate the efficacy of icotinib in treatment of advanced non -small cell lung cancer ( NSCLC)and prognosis. Methods 46 patients with pathologically proven advanced NSCLC who were admitted to Wuxi People′s Hospital from 2011 to 2013,were selected as study subjects,all cases take icotinib orally(125 mg per time,3 times a day), when tumor development or intolerant toxic and side effects were observed,the icotinib treatment was terminated. The progression-free survival( PFS),disease control rate( DCR)and toxic and side effects were evaluated. Results The median PFS of 46 cases was 6 months. According to Cox regression analysis results,smoking,pathological type,icotinib treatment and EGFR were significantly associated with median PFS(P<0. 05),while gender and ECOG score were not significantly associated with median PFS(P>0. 05). Among EGFR positive NSCLC patients,PFS of patients using icotinib as first-line therapy was significantly longer than that of patients using icotinib as second-line therapy(χ2 =10. 99,P<0. 001). Among 46 cases,CR was not found,19 cases reached PR,17 cases reached SD,10 cases reached PD,the disease control rate(DCR)was 78. 3%(36/46). The DCR of NSCLC patients did not vary significantly by gender,smoking,ECOG score,pathological type,icotinib treatment type and EGFR property(P>0. 05). No complete response occurred. The main toxic and side effects were grade 1 or 2 rash,diarrhea and elevation of transaminase,the incidence of therapy -related toxic and side effects was 26. 1%(12/46). Conclusion Icotinib is effective and safe for nonsmoking patients with EGFR mutation -positive advanced NSCLC. And for patients with EGFR mutation,icotinib should be used as the first-line treatment.关键词
癌,非小细胞肺/埃克替尼/治疗结果Key words
Carcinoma,non-small cell lung/Icotinib/Treatment outcome分类
医药卫生
